Welcome to Reuters Legal News beta. Please enjoy and provide us with your feedback as we continue to improve the Reuters Legal News experience.



Commentary Legal Action by Jenna Greene

November 18, 2021 4:31 PM EST Last Updated 11 days ago


Wait what? FDA wants 55 years to process FOIA request over vaccine data

By Jenna Greene 4 minute read





The Food and Drug Administration (FDA) headquarters in White Oak, Maryland, August 29, 2020. REUTERS/Andrew Kelly



(Reuters) - Freedom of Information Act requests are rarely speedy, but when a group of scientists asked the federal government to share the data it relied upon in licensing Pfizer's COVID-19 vaccine, the response went beyond typical bureaucratic footdragging.

As in 55 years beyond.

That's how long the Food & Drug Administration in court papers this week proposes it should be given to review and release the trove of vaccine-related documents responsive to the request. If a federal judge in Texas agrees, plaintiffs Public Health and Medical Professionals for Transparency can expect to see the full record in 2076.

Register now for FREE unlimited access to reuters.com

Register

The 1967 FOIA law requires federal agencies to respond to information requests within 20 business days. However, the time it takes to actually get the documents "will vary depending on the complexity of the request and any backlog of requests already pending at the agency," according to the government's central **FOIA website**.

Justice Department lawyers representing the FDA note in court papers that the plaintiffs are seeking a huge amount of vaccine-related material – about 329,000 pages.

releasing the information could help reassure vaccine skeptics that the shot is indeed "safe and effective and, thus, increase confidence in the Pfizer vaccine."

But the FDA can't simply turn the documents over wholesale. The records must be reviewed to redact "confidential business and trade secret information of Pfizer or BioNTech and personal privacy information of patients who participated in clinical trials," wrote DOJ lawyers in a **joint status report** filed Monday.

The FDA proposes releasing 500 pages per month on a rolling basis, noting that the branch that would handle the review has only 10 employees and is currently processing about 400 other FOIA requests.

"By processing and making interim responses based on 500-page increments, FDA will be able to provide more pages to more requesters, thus avoiding a system where a few large requests monopolize finite processing resources and where fewer requesters' requests are being fulfilled," DOJ lawyers wrote, pointing to other court decisions where the 500-page-per-month schedule was upheld.

Civil division trial lawyer Courtney Enlow referred my request for further comment to the DOJ public affairs office, which did not respond.

Plaintiffs' lawyers argue that their request should be top priority, and that the FDA should release all the material no later than March 3, 2022.

"This 108-day period is the same amount of time it took the FDA to review the responsive documents for the far more intricate task of licensing Pfizer's COVID-19 vaccine," wrote Aaron Siri of Siri & Glimstad in New York and John Howie of Howie Law in Dallas in court papers.

They also argue that <u>Title 21, subchapter F</u> of the FDA's own regulations stipulates that the agency "is to make 'immediately available' all documents underlying licensure of a vaccine."

Given the intense public interest in the vaccine, the plaintiffs' lawyers say that the FDA "should have been preparing to release (the data) simultaneously with the licensure. Instead, it has done the opposite."

Siri declined comment.

To meet the plaintiffs' proposed FOIA deadline, the FDA would have to process a daunting 80,000 pages a month. But the plaintiffs note that the FDA has 18,000 employees and a budget of \$6 billion and "has itself said that there is nothing more important than the licensure of this vaccine and being transparent about this vaccine."

To be sure, most people -- including many who sanctimoniously proclaim "I do my own research" -- lack the expertise to evaluate the information.

But the plaintiffs, who also include overseas professors from the UK, Germany, Denmark, Australia and Canada, appear to be well-positioned to do so.

As Siri and Howe argue, "Reviewing this information will settle the ongoing public debate regarding the adequacy of the FDA's review process."

U.S. District Judge Mark Pittman has set a scheduling conference for December 14 in



Jenna Greene

Jenna Greene writes about legal business and culture, taking a broad look at trends in the profession, faces behind the cases, and quirky courtroom dramas. A longtime chronicler of the legal industry and high-profile litigation, she lives in Northern California. Reach Greene at jenna.greene@thomsonreuters.com



More from Reuters

Latest in Legal

United States

U.S. imposes travel ban from eight African countries over Omicron variant November 27, 2021



Commodities

U.S. oil drilling review proposes higher fees, development curbs
November 26, 2021



Healthcare & Pharmaceuticals

U.S. President Biden calls for intellectual property protection waivers after Omicron discovery

November 26, 2021



Employment

Notice of termination can support discrimination claim -3rd Circ.

November 26, 2021

